Why the study?
Short-term dual antiplatelet therapy and DAPT de-escalation have become attractive strategies for patients with acute coronary syndrome.
Do short-term DAPT and DAPT de-escalation strategies reduce major adverse cardiovascular events and bleeding in patients with acute coronary syndromes?
Do short-term DAPT and DAPT de-escalation strategies reduce major adverse cardiovascular events and bleeding in patients with acute coronary syndromes?
In patients with acute coronary syndromes, specific DAPT de-escalation strategies may be associated with a lower risk of major bleeding and all-cause death.
Answers are grounded in this paper and cite their sources.
May guide ACS DAPT de-escalation toward inhibitor strategies to reduce bleeding and death; extends trial evidence via network ranking.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kuno et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: